Ryan Zimmerman

“And I'll echo my congrats on the first quarter out the gate here. You know, Richard, we were at SNIS. We got to hear from one of your users on, you know, how they approach VNS and stroke rehabilitation.”

“Congrats to both of you on the roles. um you know the first question i want to i want to go back to the pricing and volume dynamics in china for a minute here you know warren i was struck by your comments about a third of the lenses in china are evo plus and you know let's assume that you know there's a 30 40 percent…”

“I appreciate your thoughts, Damien, one year post the position. Maybe to begin, I'd like to drill into U.S. Recon for a moment here. You know, you saw really nice growth, particularly in the hips and knees business.”

“So I'm not sure if there's something I'm missing there, or I guess why not just take the full year total revenue guidance down somewhat just given the procedure reduction that we've seen here.”

“Preston, you've talked enough about the top line, I think, with the questions. But can you spend a little bit on margins and the EPS guide, particularly in the back half of the year?”